Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

VIKAS LIFECARE LTD.

NSE : VIKASLIFEBSE : 542655ISIN CODE : INE161L01027Industry : PetrochemicalsHouse : Private

BSE2.550 (0 %)

PREV CLOSE ( ) 2.55

OPEN PRICE ( ) 2.55

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 2054178

TODAY'S LOW / HIGH ( )2.53 2.58

52 WK LOW / HIGH ( )2.22 6.01

NSE2.54-0.01 (-0.39 %)

PREV CLOSE( ) 2.55

OPEN PRICE ( ) 2.56

BID PRICE (QTY) 2.54 (1361)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 7486292

TODAY'S LOW / HIGH( ) 2.53 2.60

52 WK LOW / HIGH ( )2.28 6.03

Select year

Particulars

Mar 2024

Mar 2023

Mar 2022

Mar 2021

Operational & Financial Ratios

Earnings Per Share (Rs)

0.08

-0.11

0.26

-0.05

CEPS(Rs)

0.10

-0.09

0.28

-0.04

DPS(Rs)

0.00

Book NAV/Share(Rs)

2.76

2.30

1.82

1.00

Tax Rate(%)

21.24

27.41

25.94

-133.48

Margin Ratios

Core EBITDA Margin(%)

0.97

-4.19

-0.31

10.36

EBIT Margin(%)

4.47

-4.00

13.64

5.13

Pre Tax Margin(%)

3.83

-4.49

12.93

-2.00

PAT Margin (%)

3.01

-3.26

9.57

-4.67

Cash Profit Margin (%)

3.83

-2.62

10.07

-3.76

Performance Ratios

ROA(%)

2.66

-3.99

12.29

-2.34

ROE(%)

3.42

-5.85

21.76

-5.25

ROCE(%)

4.57

-6.53

24.93

3.55

Asset Turnover(x)

0.88

1.23

1.28

0.50

Sales/Fixed Asset(x)

8.19

12.48

18.32

10.33

Working Capital/Sales(x)

2.46

4.41

22.41

1.35

Efficiency Ratios

Fixed Capital/Sales(x)

0.12

0.08

0.05

0.10

Receivable days

128.90

81.29

68.82

346.82

Inventory Days

8.89

15.72

33.60

132.24

Payable days

32.02

50.92

65.69

216.94

Valuation Parameters

PER(x)

57.13

0.00

20.35

0.00

PCE(x)

46.86

-38.85

19.17

-69.00

Price/Book(x)

1.76

1.47

2.93

2.92

Yield(%)

0.00

EV/Net Sales(x)

1.84

1.06

1.99

3.15

EV/Core EBITDA(x)

26.97

-31.46

14.03

26.87

EV/EBIT(x)

41.21

-26.57

14.53

61.32

EV/CE(x)

1.61

1.40

1.86

1.58

M Cap / Sales

1.80

1.02

1.94

2.59

Growth Ratio

Net Sales Growth(%)

-6.37

58.20

301.26

0.00

Core EBITDA Growth(%)

289.35

-137.68

386.53

0.00

EBIT Growth(%)

204.63

-146.23

971.74

0.00

PAT Growth(%)

186.75

-153.58

926.65

0.00

EPS Growth(%)

179.72

-140.74

595.08

0.00

Financial Stability Ratios

Total Debt/Equity(x)

0.08

0.09

0.12

0.63

Current Ratio(x)

4.35

2.01

1.13

1.84

Quick Ratio(x)

4.18

1.89

0.86

1.43

Interest Cover(x)

6.96

-8.28

19.12

0.72

Total Debt/Mcap(x)

0.04

0.06

0.04

0.21